A Phase 1/2 interventional study of Nivolumab and Sorafenib in Hepatocellular Carcinoma, sponsored by Bristol-Myers Squibb. Completed at 60 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-24.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing nivolumab in Carcinoma, Hepatocellular — 11 open to participants now, 17 under way, 1 of them phase 3. Nivolumab · Carcinoma, Hepatocellular.
Among the 53 studies testing nivolumab in Carcinoma, Hepatocellular, this one is the 5th largest by enrollment, is the only one that started in 2012, is one of 6 in phase 1/2, and was the 1st registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.
Browse Carcinoma, Hepatocellular studies →11 of the 53 studies testing nivolumab in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:
University of Texas Southwestern Medical Center · Sites in United States
Ages 18+
University of Hawaii · Sites in United States
Ages 18+
West China Hospital · Sites in China
Ages 18–80
Diwakar Davar · Sites in United States
Ages 18+
National University Hospital, Singapore · Sites in Singapore
Ages 21–99
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 36 · Phase 3 6
First in 2012; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 657 is above the median of 54 across 2,620 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 40 across the 53 interventional studies. Of the 32 that completed or were terminated, 10 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 53 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
21 studies in Carcinoma, Hepatocellular by Bristol-Myers Squibb: 3 open now, 4 under way, 1 of them phase 3. Of 17 finished, 8 (47%) have results posted.
Among the 21 studies in Carcinoma, Hepatocellular by Bristol-Myers Squibb, this one is the 4th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2012, is one of 7 in phase 1/2, and was the 8th registered.
Bristol-Myers Squibb’s Carcinoma, Hepatocellular studies by the year they started, since 2006.
5 of the studies testing nivolumab in Carcinoma, Hepatocellular that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04472767University of California, IrvineCabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | 2027-01-31 |
| NCT06265285Mayo ClinicComparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | 2027-05-01 |
| NCT07919717Shanghai Zhongshan HospitalNIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC | 2027-05-12 |
| NCT07075120University of HawaiiIpilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer | 2027-08-01 |
| NCT05475613Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityDownstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation | 2027-08-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 53 studies testing nivolumab in Carcinoma, Hepatocellular, from their registry updates:
Among Bristol-Myers Squibb’s 21 in Carcinoma, Hepatocellular:
This tab as a report to print or save as PDF → With an account.
The first part of the study is the Dose Escalation Phase designed to establish the safety of nivolumab at different dose levels for each of the three cohorts (uninfected hepatocellular carcinoma (HCC) subjects, hepatitis C virus (HCV)-infected HCC subjects, and hepatitis B virus (HBV)-infected subjects).
The second part of the study is the Expansion Phase designed to generate additional clinical data at specified doses for each of the 3 cohorts. A third cohort has been added in this study to compare the efficacy of nivolumab and sorafenib in the treatment of Advanced HCC. A fourth cohort will generate data on the safety and efficacy of the combination nivolumab plus ipilimumab in the treatment of Advanced HCC. In the fifth cohort, additional clinical data will be generated for Child-Pugh B subjects. A Cabozantinib Combination Cohort has been added to evaluate the safety and tolerability of nivolumab in combination with cabozantinib and nivolumab with ipilimumab in combination with cabozantinib.
Study Classification: Pharmacokinetics/Pharmacodynamics
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nivolumab intravenous solution on specific days
Biological: Nivolumab
Nivolumab intravenous solution on specific days
Biological: Nivolumab
Nivolumab intravenous solution on specific days
Biological: Nivolumab
Nivolumab intravenous solution on specific days
Biological: Nivolumab
Sorafenib tablets on specific days
Drug: Sorafenib
Nivolumab intravenous solution + Ipilimumab intravenous solution on specific days
Biological: Nivolumab · Drug: Ipilimumab
Nivolumab intravenous solution on specific days
Biological: Nivolumab
Nivolumab intravenous solution + cabozantinib oral tablets on specific days
Drug: Cabozantinib
Nivolumab intravenous solution + Ipilimumab intravenous solution + cabozantinib oral tablets on specific days
Drug: Cabozantinib
Also known as: BMS-936558
Number of Participants With Adverse Events (AEs)
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Time frame: From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)
Number of Participants With Serious Adverse Events (SAEs)
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.
Time frame: From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)
Number of Participants With Adverse Events Leading to Discontinuation
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Time frame: From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)
Number of Participants Who Died
Number of participants who died during the study.
Time frame: From first dose of study medication until study closure (Up to approximately 144 months)
Number of Participants With Laboratory Abnormalities in Specific Liver Tests
Participants with abnormalities in liver function tests related to potential drug-induced liver injury. Blood samples were collected and analyzed for liver function parameters, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Abnormalities were assessed relative to the upper limit of normal (ULN) for each parameter. Abbreviations: ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; ULN = Upper Limit of Normal.
Time frame: From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)
Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests
Number of participants with thyroid-related laboratory abnormalities during the study. Blood samples were collected and analyzed for thyroid function markers (FT3, FT4). Abnormalities were assessed against LLN and ULN for each parameter. Abbreviations: FT3 = Free T3; FT4 = Free T4; LLN = Lower Limit of Normal; ULN = Upper Limit of Normal; TSH = Thyroid Stimulating Hormone
Time frame: From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)
Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) for Cohort 2
Objective response rate (ORR) is defined as the percent of all treated participants whose best overall response (BOR) is either complete response (CR) or partial response (PR) by BICR per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).
Time frame: From the start of the study treatment until disease progression, or the date of subsequent anti-cancer therapy, whichever occurs first (Up to approximately 144 months)
Objective Response Rate (ORR) by Investigator for Cohorts 3, 4, 5, and 6
Objective response rate (ORR) is defined as the percent of all treated participants whose best overall response (BOR) is either complete response (CR) or partial response (PR) by Investigator per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).
Time frame: From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 5) until disease progression, or the date of subsequent anti-cancer therapy, whichever occurs first (Up to approximately 144 months)
Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) for Cohort 1
Objective response rate (ORR) is defined as the percent of all treated participants whose best overall response (BOR) is either complete response (CR) or partial response (PR) by BICR per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).
Time frame: From the start of the study treatment until disease progression, or the date of subsequent anti-cancer therapy, whichever occurs first (Up to approximately 144 months)
Number of Participants With Complete Response (CR) Assessed by Blinded Independent Central Review (BICR)
The number of participants whose best overall response (BOR) is CR in the population of interest. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.
Time frame: From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) up to approximately 144 months after first dose
Disease Control Rate (DCR) Assessed by Blinded Independent Central Review (BICR)
The percentage of participants whose best overall response (BOR) is CR, PR or SD in the population of interest. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Failure to meet criteria for complete or partial response, in the absence of progressive disease. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).
Time frame: From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) until disease progression, or the date of subsequent anti-cancer therapy, whichever occurs first (Up to approximately 144 months)
Duration of Response (DOR) Assessed by Blinded Independent Central Review (BICR)
DOR is defined as the time from the first documented objective response (either complete or partial response) until the date of disease progression or death from any cause, whichever occurs first. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).
Time frame: From first documented response to first documented progression or death, whichever occurs first (Up to approximately 144 months)
Time to Response (TTR) Assessed by Blinded Independent Central Review (BICR)
Time to Response (TTR) defined as the time from randomization to the date of the first confirmed CR or PR for Cohort 3, 4 and 6, and from the first dosing date of study medication to the date of the first confirmed CR or PR for cohort 1, 2 and 5. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) to the date of attainment of complete response (CR) or partial response (PR) (up to approximately 144 months)
Time to Progression (TTP) Assessed by Blinded Independent Central Review (BICR)
Time to Progression (TTP) is defined from the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) to the date of the first objectively documented disease progression. Participants who have not progressed as assessed by radiography will be censored at the last tumor assessment date prior to subsequent anti-cancer therapy. Participants who have no on-study tumor assessments were censored at the date of randomization. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).
Time frame: From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (Up to approximately 144 months)
Time to Progression (TTP) Rate Assessed by Blinded Independent Central Review (BICR)
TTP rate is defined as the percentage of participants without disease progression at select time points (milestones) during the study. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).
Time frame: At 6 and 12 months
Progression Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR)
PFS is defined as the time from randomization date or first dosing date of study medication to the date of the first objectively documented tumor progression or death due to any cause. Participants who die without a reported prior progression will be considered to have progressed on the date of their death. Participants who did not progress or die will be censored on the date of their last tumor assessment. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).
Time frame: From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) up to documented disease progression or death, whichever occurs first (up to approximately 144 months)
Overall Survival (OS)
OS is defined as the time from randomization date or first dosing date of study medication to the date of death (due to any cause). Participants who were alive were censored at the last known alive dates.
Time frame: From the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) up to the date of death or date last known alive (up to approximately 144 months)
Overall Survival (OS) Rate
OS rate is defined as the percentage of participants who are still alive at certain time points during the study.
Time frame: At 6, 12, 24, 48 and 60 months
Maximum Observed Serum Concentration (Cmax)
Cmax is the maximum observed serum concentration.
Time frame: At Cycle 1 Day 1 and Cycle 3 Day 1 (Each Cycle = 2 Weeks)
Time of Maximum Observed Serum Concentration (Tmax)
Tmax is the time taken to reach the maximum observed serum concentration (Cmax).
Time frame: At Cycle 1 Day 1 and Cycle 3 Day 1 (Each Cycle = 2 Weeks)
Area Under the Serum Concentration Time Curve in the Dosing Interval [AUC(TAU)]
AUC (TAU) is the area measured under the concentration-time curve taken over the dosing interval.
Time frame: At Cycle 1 Day 1 and Cycle 3 Day 1 (Each Cycle = 2 Weeks)
Serum Concentration Achieved at the End of Dosing Interval (Trough Concentration) (Ctrough)
Ctrough is the lowest observed serum concentration.
Time frame: At Cycle 1 Day 1 and Cycle 3 Day 1 (Each Cycle = 2 Weeks)
Serum Concentration Achieved at the End of the Infusion (Ceoinf)
Serum Concentration Achieved at the End of the Infusion (Ceoinf) refers to the amount of drug present in the blood (serum) immediately after the completion of an infusion. It represents the concentration measured at the exact time the infusion ends, before any significant elimination or distribution occurs.
Time frame: At Cycle 1 Day 1 and Cycle 3 Day 1 (Each Cycle = 2 Weeks)
Ratio of an Exposure Measure at Steady State to That After the First Dose (Exposure Measure Includes Cmax) (AI_Cmax)
AI\_Cmax is ratio of an exposure measure at steady state to that after the first dose (exposure measure includes Cmax)
Time frame: At Cycle 3 Day 1 (Each Cycle = 2 Weeks)
Accumulation Index Ratio of AUC at Steady State to That After the First Dose (AI_AUC)
AI\_AUC is accumulation index ratio of AUC at steady state to that after the first dose
Time frame: At Cycle 3 Day 1 (Each Cycle = 2 Weeks)
Effective T-Half (T-HALF)
Effective half-life is defined as the time it takes for the amount of a drug in the body to decrease by half.
Time frame: At Cycle 3 Day 1 (Each Cycle = 2 Weeks)
Number of Participants With Anti-drug Antibodies (ADA)
Baseline ADA Positive: Participant with baseline ADA-positive sample ADA Positive: Participant with at least one ADA-positive sample relative to baseline Persistent Positive (PP): ADA-positive sample at 2 or more consecutive timepoints Not PP-Last Sample Positive: Not persistent but with ADA-positive sample at the last sampling timepoint Other Positive: Not persistent but some ADA-positive samples with the last sample being negative ADA Negative: Participant with no ADA-positive sample after initiation of treatment
Time frame: From first dose of study medication through 100 days following last dose of study treatment (Assessed approximately 04 months up to a max of approximately 106 months)
| Milestone | Cohort 1 Uninfected HCC: Treatment 1 | Cohort 1 Uninfected HCC: Treatment 2 | Cohort 1 Uninfected HCC: Treatment 3 | Cohort 1 Uninfected HCC: Treatment 4 | Cohort 1 Uninfected HCC: Treatment 5 | Cohort 1 HCV Infected: Treatment 6 | Cohort 1 HCV Infected: Treatment 7 | Cohort 1 HCV Infected: Treatment 8 | Cohort 1 HBV Infected: Treatment 9 | Cohort 1 HBV Infected: Treatment 10 | Cohort 1 HBV Infected: Treatment 11 | Cohort 1 HBV Infected: Treatment 12 | Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1 | Cohort 2 Uninfected Sorafenib Progressors: Treatment 2 | Cohort 2 HCV Infected: Treatment 3 | Cohort 2 HBV Infected: Treatment 4 | Cohort 3: Treatment 1 | Cohort 3: Treatment 2 | Cohort 4: Treatment 1 | Cohort 4: Treatment 2 | Cohort 4: Treatment 3 | Cohort 5: Treatment 1 | Cohort 6: Treatment 1 | Cohort 6: Treatment 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 3 | 3 | 3 | 13 | 3 | 4 | 3 | 5 | 3 | 3 | 4 | 56 | 57 | 50 | 51 | 61 | 66 | 50 | 49 | 49 | 49 | 36 | 35 |
| Randomized | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 61 | 66 | 50 | 49 | 49 | 0 | 36 | 35 |
| Completed | 1 | 3 | 3 | 3 | 13 | 3 | 4 | 3 | 5 | 3 | 3 | 4 | 56 | 57 | 50 | 51 | 60 | 62 | 49 | 49 | 48 | 49 | 36 | 35 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 1 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Cohort 1 Uninfected HCC: Treatment 1 | Cohort 1 Uninfected HCC: Treatment 2 | Cohort 1 Uninfected HCC: Treatment 3 | Cohort 1 Uninfected HCC: Treatment 4 | Cohort 1 Uninfected HCC: Treatment 5 | Cohort 1 HCV Infected: Treatment 6 | Cohort 1 HCV Infected: Treatment 7 | Cohort 1 HCV Infected: Treatment 8 | Cohort 1 HBV Infected: Treatment 9 | Cohort 1 HBV Infected: Treatment 10 | Cohort 1 HBV Infected: Treatment 11 | Cohort 1 HBV Infected: Treatment 12 | Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1 | Cohort 2 Uninfected Sorafenib Progressors: Treatment 2 | Cohort 2 HCV Infected: Treatment 3 | Cohort 2 HBV Infected: Treatment 4 | Cohort 3: Treatment 1 | Cohort 3: Treatment 2 | Cohort 4: Treatment 1 | Cohort 4: Treatment 2 | Cohort 4: Treatment 3 | Cohort 5: Treatment 1 | Cohort 6: Treatment 1 | Cohort 6: Treatment 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 3 | 3 | 3 | 13 | 3 | 4 | 3 | 5 | 3 | 3 | 4 | 56 | 57 | 50 | 51 | 60 | 62 | 49 | 49 | 48 | 49 | 36 | 35 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 3 | 3 | 3 | 13 | 3 | 4 | 3 | 5 | 3 | 3 | 4 | 56 | 57 | 50 | 51 | 60 | 62 | 49 | 49 | 48 | 49 | 36 | 35 |
| Withdrew: Disease progression | 1 | 3 | 2 | 1 | 13 | 3 | 4 | 3 | 5 | 3 | 3 | 4 | 43 | 48 | 33 | 46 | 41 | 42 | 28 | 37 | 37 | 39 | 27 | 19 |
| Withdrew: Study drug toxicity | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 1 | 5 | 0 | 5 | 10 | 12 | 4 | 2 | 3 | 2 | 6 |
| Withdrew: Maximum clinical benefit | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other reasons | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 1 | 1 | 3 | 1 | 4 | 0 | 0 | 4 |
| Withdrew: Participant no longer meets study criteria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Poor/non-compliance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Participant withdrew consent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 2 | 1 | 2 | 1 | 0 | 2 | 2 |
| Withdrew: Participant request to discontinue study treatment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 3 | 2 | 1 | 2 | 0 | 1 | 1 | 2 | 0 | 1 |
| Withdrew: Adverse event related to study drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 3 | 3 | 2 | 3 | 3 | 4 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
| Participants | Cohort 1 Uninfected HCC: Treatment 1 | Cohort 1 Uninfected HCC: Treatment 2 | Cohort 1 Uninfected HCC: Treatment 3 | Cohort 1 Uninfected HCC: Treatment 4 | Cohort 1 Uninfected HCC: Treatment 5 | Cohort 1 HCV Infected: Treatment 6 | Cohort 1 HCV Infected: Treatment 7 | Cohort 1 HCV Infected: Treatment 8 | Cohort 1 HBV Infected: Treatment 9 | Cohort 1 HBV Infected: Treatment 10 | Cohort 1 HBV Infected: Treatment 11 | Cohort 1 HBV Infected: Treatment 12 | Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1 | Cohort 2 Uninfected Sorafenib Progressors: Treatment 2 | Cohort 2 HCV Infected: Treatment 3 | Cohort 2 HBV Infected: Treatment 4 | Cohort 3: Treatment 1 | Cohort 3: Treatment 2 | Cohort 4: Treatment 1 | Cohort 4: Treatment 2 | Cohort 4: Treatment 3 | Cohort 5: Treatment 1 | Cohort 6: Treatment 1 | Cohort 6: Treatment 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) | 1 | 3 | 3 | 3 | 13 | 3 | 4 | 3 | 5 | 3 | 3 | 4 | 56 | 56 | 50 | 51 | 58 | 59 | 48 | 47 | 48 | 47 | 36 | 35 |
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.
| Participants | Cohort 1 Uninfected HCC: Treatment 1 | Cohort 1 Uninfected HCC: Treatment 2 | Cohort 1 Uninfected HCC: Treatment 3 | Cohort 1 Uninfected HCC: Treatment 4 | Cohort 1 Uninfected HCC: Treatment 5 | Cohort 1 HCV Infected: Treatment 6 | Cohort 1 HCV Infected: Treatment 7 | Cohort 1 HCV Infected: Treatment 8 | Cohort 1 HBV Infected: Treatment 9 | Cohort 1 HBV Infected: Treatment 10 | Cohort 1 HBV Infected: Treatment 11 | Cohort 1 HBV Infected: Treatment 12 | Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1 | Cohort 2 Uninfected Sorafenib Progressors: Treatment 2 | Cohort 2 HCV Infected: Treatment 3 | Cohort 2 HBV Infected: Treatment 4 | Cohort 3: Treatment 1 | Cohort 3: Treatment 2 | Cohort 4: Treatment 1 | Cohort 4: Treatment 2 | Cohort 4: Treatment 3 | Cohort 5: Treatment 1 | Cohort 6: Treatment 1 | Cohort 6: Treatment 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 0 | 1 | 2 | 0 | 5 | 0 | 3 | 1 | 5 | 3 | 0 | 2 | 34 | 28 | 29 | 21 | 27 | 25 | 30 | 27 | 29 | 31 | 17 | 21 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
| Participants | Cohort 1 Uninfected HCC: Treatment 1 | Cohort 1 Uninfected HCC: Treatment 2 | Cohort 1 Uninfected HCC: Treatment 3 | Cohort 1 Uninfected HCC: Treatment 4 | Cohort 1 Uninfected HCC: Treatment 5 | Cohort 1 HCV Infected: Treatment 6 | Cohort 1 HCV Infected: Treatment 7 | Cohort 1 HCV Infected: Treatment 8 | Cohort 1 HBV Infected: Treatment 9 | Cohort 1 HBV Infected: Treatment 10 | Cohort 1 HBV Infected: Treatment 11 | Cohort 1 HBV Infected: Treatment 12 | Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1 | Cohort 2 Uninfected Sorafenib Progressors: Treatment 2 | Cohort 2 HCV Infected: Treatment 3 | Cohort 2 HBV Infected: Treatment 4 | Cohort 3: Treatment 1 | Cohort 3: Treatment 2 | Cohort 4: Treatment 1 | Cohort 4: Treatment 2 | Cohort 4: Treatment 3 | Cohort 5: Treatment 1 | Cohort 6: Treatment 1 | Cohort 6: Treatment 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Adverse Events Leading to Discontinuation | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 4 | 8 | 10 | 3 | 14 | 16 | 16 | 7 | 10 | 8 | 7 | 12 |
Number of participants who died during the study.
| Participants | Cohort 1 Uninfected HCC: Treatment 1 | Cohort 1 Uninfected HCC: Treatment 2 | Cohort 1 Uninfected HCC: Treatment 3 | Cohort 1 Uninfected HCC: Treatment 4 | Cohort 1 Uninfected HCC: Treatment 5 | Cohort 1 HCV Infected: Treatment 6 | Cohort 1 HCV Infected: Treatment 7 | Cohort 1 HCV Infected: Treatment 8 | Cohort 1 HBV Infected: Treatment 9 | Cohort 1 HBV Infected: Treatment 10 | Cohort 1 HBV Infected: Treatment 11 | Cohort 1 HBV Infected: Treatment 12 | Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1 | Cohort 2 Uninfected Sorafenib Progressors: Treatment 2 | Cohort 2 HCV Infected: Treatment 3 | Cohort 2 HBV Infected: Treatment 4 | Cohort 3: Treatment 1 | Cohort 3: Treatment 2 | Cohort 4: Treatment 1 | Cohort 4: Treatment 2 | Cohort 4: Treatment 3 | Cohort 5: Treatment 1 | Cohort 6: Treatment 1 | Cohort 6: Treatment 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Died | 1 | 3 | 2 | 2 | 13 | 1 | 4 | 3 | 5 | 3 | 3 | 4 | 49 | 52 | 40 | 45 | 52 | 53 | 35 | 41 | 40 | 48 | 29 | 26 |
Participants with abnormalities in liver function tests related to potential drug-induced liver injury. Blood samples were collected and analyzed for liver function parameters, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Abnormalities were assessed relative to the upper limit of normal (ULN) for each parameter. Abbreviations: ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; ULN = Upper Limit of Normal.
| Participants | Cohort 1 Uninfected HCC: Treatment 1 | Cohort 1 Uninfected HCC: Treatment 2 | Cohort 1 Uninfected HCC: Treatment 3 | Cohort 1 Uninfected HCC: Treatment 4 | Cohort 1 Uninfected HCC: Treatment 5 | Cohort 1 HCV Infected: Treatment 6 | Cohort 1 HCV Infected: Treatment 7 | Cohort 1 HCV Infected: Treatment 8 | Cohort 1 HBV Infected: Treatment 9 | Cohort 1 HBV Infected: Treatment 10 | Cohort 1 HBV Infected: Treatment 11 | Cohort 1 HBV Infected: Treatment 12 | Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1 | Cohort 2 Uninfected Sorafenib Progressors: Treatment 2 | Cohort 2 HCV Infected: Treatment 3 | Cohort 2 HBV Infected: Treatment 4 | Cohort 3: Treatment 1 | Cohort 3: Treatment 2 | Cohort 4: Treatment 1 | Cohort 4: Treatment 2 | Cohort 4: Treatment 3 | Cohort 5: Treatment 1 | Cohort 6: Treatment 1 | Cohort 6: Treatment 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT or AST > 3 X Upper limit of Normal (ULN) | 0 | 1 | 1 | 1 | 7 | 2 | 4 | 1 | 2 | 0 | 2 | 2 | 22 | 20 | 32 | 12 | 23 | 21 | 29 | 25 | 23 | 27 | 23 | 21 |
| Alanine Transaminase (ALT) OR AST > 5 X ULN | 0 | 1 | 1 | 1 | 0 | 2 | 2 | 1 | 2 | 0 | 2 | 1 | 10 | 10 | 22 | 5 | 9 | 7 | 22 | 14 | 11 | 17 | 12 | 19 |
| ALT or Aspartate Transaminase (AST) > 10 X ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 4 | 5 | 10 | 4 | 3 | 2 | 8 | 7 | 7 | 2 | 5 | 9 |
| ALT or AST > 15 X ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 3 | 3 | 1 | 3 | 2 | 2 | 3 | 2 | 1 | 1 | 3 |
| ALT or AST > 20 X ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 2 | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 0 | 2 |
| Total Bilirubin > 2 X ULN | 0 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 5 | 9 | 10 | 6 | 13 | 12 | 11 | 9 | 2 | 17 | 5 | 8 |
| Total Bilirubin > 8 X ULN | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 3 | 0 | 5 | 4 | 0 | 1 | 0 | 1 |
| Total Bilirubin >8XULN if Elevated at Entry Or >5XULN if Normal at Entry | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 1 | 3 | 0 | 5 | 4 | 0 | 2 | 0 | 1 |
| Concurrent ALT OR AST Elevation > 3 X ULN with Total Bilirubin > 2 X ULN within One Day | 0 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 3 | 6 | 7 | 5 | 9 | 10 | 9 | 7 | 1 | 10 | 4 | 7 |
| Concurrent ALT or AST elevation > 3 X ULN with Total Bilirubin > 2 X ULN within 30 Days | 0 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 3 | 6 | 7 | 5 | 9 | 11 | 9 | 7 | 1 | 11 | 4 | 7 |
| Concurrent Alt>=10XULN & Total Bilirubin >=2XULN Or 2X Baseline if Elevated Total Bilirubin at Entry | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
Number of participants with thyroid-related laboratory abnormalities during the study. Blood samples were collected and analyzed for thyroid function markers (FT3, FT4). Abnormalities were assessed against LLN and ULN for each parameter. Abbreviations: FT3 = Free T3; FT4 = Free T4; LLN = Lower Limit of Normal; ULN = Upper Limit of Normal; TSH = Thyroid Stimulating Hormone
| Participants | Cohort 1 Uninfected HCC: Treatment 1 | Cohort 1 Uninfected HCC: Treatment 2 | Cohort 1 Uninfected HCC: Treatment 3 | Cohort 1 Uninfected HCC: Treatment 4 | Cohort 1 Uninfected HCC: Treatment 5 | Cohort 1 HCV Infected: Treatment 6 | Cohort 1 HCV Infected: Treatment 7 | Cohort 1 HCV Infected: Treatment 8 | Cohort 1 HBV Infected: Treatment 9 | Cohort 1 HBV Infected: Treatment 10 | Cohort 1 HBV Infected: Treatment 11 | Cohort 1 HBV Infected: Treatment 12 | Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1 | Cohort 2 Uninfected Sorafenib Progressors: Treatment 2 | Cohort 2 HCV Infected: Treatment 3 | Cohort 2 HBV Infected: Treatment 4 | Cohort 3: Treatment 1 | Cohort 3: Treatment 2 | Cohort 4: Treatment 1 | Cohort 4: Treatment 2 | Cohort 4: Treatment 3 | Cohort 5: Treatment 1 | Cohort 6: Treatment 1 | Cohort 6: Treatment 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TSH > ULN (Upper Limit of Normal) | 0 | 1 | 1 | 1 | 5 | 1 | 1 | 3 | 0 | 1 | 0 | 1 | 20 | 23 | 21 | 17 | 15 | 19 | 23 | 15 | 15 | 6 | 21 | 17 |
| TSH > ULN with TSH <= ULN at baseline | 0 | 0 | 1 | 0 | 3 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 15 | 17 | 13 | 11 | 11 | 15 | 18 | 11 | 9 | 5 | 20 | 14 |
| TSH > ULN with at least one FT3/FT4 test value < LLN (Lower Limit of Normal) | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 1 | 7 | 14 | 6 | 5 | 6 | 6 | 10 | 8 | 4 | 3 | 6 | 7 |
| TSH > ULN with all other FT3/FT4 test values >= LLN | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 11 | 8 | 14 | 10 | 6 | 9 | 11 | 4 | 5 | 3 | 11 | 6 |
| TSH > ULN with FT3/FT4 test missing | 0 | 1 | 1 | 1 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 2 | 3 | 4 | 2 | 3 | 6 | 0 | 4 | 4 |
| TSH < LLN | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 10 | 7 | 8 | 9 | 2 | 6 | 16 | 13 | 10 | 5 | 6 | 9 |
| TSH < LLN with TSH >= LLN at baseline | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 6 | 7 | 7 | 7 | 2 | 4 | 15 | 12 | 9 | 5 | 4 | 9 |
| TSH < LLN with at least one FT3/FT4 test value > ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 3 | 4 | 1 | 1 | 2 | 9 | 6 | 6 | 2 | 2 | 5 |
| TSH < LLN with all other FT3/FT4 test values <= ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 4 | 3 | 8 | 1 | 4 | 5 | 2 | 3 | 1 | 3 | 4 |
| TSH < LLN with FT3/FT4 test missing | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 2 | 5 | 1 | 2 | 1 | 0 |
Objective response rate (ORR) is defined as the percent of all treated participants whose best overall response (BOR) is either complete response (CR) or partial response (PR) by BICR per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).
| Percent of Participants | Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1 | Cohort 2 Uninfected Sorafenib Progressors: Treatment 2 | Cohort 2 HCV Infected: Treatment 3 | Cohort 2 HBV Infected: Treatment 4 |
|---|---|---|---|---|
| Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) for Cohort 2 | 19.6 (10.2 to 32.4) | 14.0 (6.3 to 25.8) | 20.0 (10.0 to 33.7) | 13.7 (5.7 to 26.3) |
Objective response rate (ORR) is defined as the percent of all treated participants whose best overall response (BOR) is either complete response (CR) or partial response (PR) by Investigator per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).
| Percent of Participants | Cohort 3: Treatment 1 | Cohort 3: Treatment 2 | Cohort 4: Treatment 1 | Cohort 4: Treatment 2 | Cohort 4: Treatment 3 | Cohort 5: Treatment 1 | Cohort 6: Treatment 1 | Cohort 6: Treatment 2 |
|---|---|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) by Investigator for Cohorts 3, 4, 5, and 6 | 11.5 (4.7 to 22.2) | 4.5 (0.9 to 12.7) | 36.0 (22.9 to 50.8) | 26.5 (14.9 to 41.1) | 28.6 (16.6 to 43.3) | 12.2 (4.6 to 24.8) | 16.7 (6.4 to 32.8) | 25.7 (12.5 to 43.3) |
Objective response rate (ORR) is defined as the percent of all treated participants whose best overall response (BOR) is either complete response (CR) or partial response (PR) by BICR per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).
| Percent of Participants | Cohort 1 Uninfected HCC | Cohort 1 HCV Infected | Cohort 1 HBV Infected |
|---|---|---|---|
| Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) for Cohort 1 | 13.0 (2.8 to 33.6) | 20.0 (2.5 to 55.6) | 13.3 (1.7 to 40.5) |
The number of participants whose best overall response (BOR) is CR in the population of interest. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.
| Participants | Cohort 1 Uninfected HCC | Cohort 1 HCV Infected | Cohort 1 HBV Infected | Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1 | Cohort 2 Uninfected Sorafenib Progressors: Treatment 2 | Cohort 2 HCV Infected: Treatment 3 | Cohort 2 HBV Infected: Treatment 4 | Cohort 3: Treatment 1 | Cohort 3: Treatment 2 | Cohort 4: Treatment 1 | Cohort 4: Treatment 2 | Cohort 4: Treatment 3 | Cohort 5: Treatment 1 | Cohort 6: Treatment 1 | Cohort 6: Treatment 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Complete Response (CR) Assessed by Blinded Independent Central Review (BICR) | 1 | 0 | 0 | 2 | 0 | 2 | 4 | 1 | 1 | 4 | 4 | 1 | 0 | 1 | 3 |
The percentage of participants whose best overall response (BOR) is CR, PR or SD in the population of interest. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Failure to meet criteria for complete or partial response, in the absence of progressive disease. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).
| Percent of Participants | Cohort 1 Uninfected HCC | Cohort 1 HCV Infected | Cohort 1 HBV Infected | Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1 | Cohort 2 Uninfected Sorafenib Progressors: Treatment 2 | Cohort 2 HCV Infected: Treatment 3 | Cohort 2 HBV Infected: Treatment 4 | Cohort 3: Treatment 1 | Cohort 3: Treatment 2 | Cohort 4: Treatment 1 | Cohort 4: Treatment 2 | Cohort 4: Treatment 3 | Cohort 5: Treatment 1 | Cohort 6: Treatment 1 | Cohort 6: Treatment 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disease Control Rate (DCR) Assessed by Blinded Independent Central Review (BICR) | 47.8 (26.8 to 69.4) | 70.0 (34.8 to 93.3) | 40.0 (16.3 to 67.7) | 66.1 (52.2 to 78.2) | 56.1 (42.4 to 69.3) | 54.0 (39.3 to 68.2) | 47.1 (32.9 to 61.5) | 52.5 (39.3 to 65.4) | 62.1 (49.3 to 73.8) | 54.0 (39.3 to 68.2) | 42.9 (28.8 to 57.8) | 49.0 (34.4 to 63.7) | 44.9 (30.7 to 59.8) | 77.8 (60.8 to 89.9) | 80.0 (63.1 to 91.6) |
DOR is defined as the time from the first documented objective response (either complete or partial response) until the date of disease progression or death from any cause, whichever occurs first. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).
| Months | Cohort 1 Uninfected HCC | Cohort 1 HCV Infected | Cohort 1 HBV Infected | Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1 | Cohort 2 Uninfected Sorafenib Progressors: Treatment 2 | Cohort 2 HCV Infected: Treatment 3 | Cohort 2 HBV Infected: Treatment 4 | Cohort 3: Treatment 1 | Cohort 3: Treatment 2 | Cohort 4: Treatment 1 | Cohort 4: Treatment 2 | Cohort 4: Treatment 3 | Cohort 5: Treatment 1 | Cohort 6: Treatment 1 | Cohort 6: Treatment 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Duration of Response (DOR) Assessed by Blinded Independent Central Review (BICR) | NA (8.74 to NA) | 12.55 (5.75 to NA) | 6.41 (2.83 to NA) | 22.57 (5.62 to 31.80) | 11.30 (5.55 to NA) | NA (3.15 to NA) | NA (8.31 to NA) | 5.21 (2.10 to NA) | 9.26 (5.45 to NA) | 17.48 (8.31 to 52.47) | 22.21 (9.36 to NA) | 16.59 (4.34 to 48.20) | 18.40 (NA to NA) | 21.55 (10.84 to NA) | 49.51 (7.72 to NA) |
Time to Response (TTR) defined as the time from randomization to the date of the first confirmed CR or PR for Cohort 3, 4 and 6, and from the first dosing date of study medication to the date of the first confirmed CR or PR for cohort 1, 2 and 5. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| Months | Cohort 1 Uninfected HCC | Cohort 1 HCV Infected | Cohort 1 HBV Infected | Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1 | Cohort 2 Uninfected Sorafenib Progressors: Treatment 2 | Cohort 2 HCV Infected: Treatment 3 | Cohort 2 HBV Infected: Treatment 4 | Cohort 3: Treatment 1 | Cohort 3: Treatment 2 | Cohort 4: Treatment 1 | Cohort 4: Treatment 2 | Cohort 4: Treatment 3 | Cohort 5: Treatment 1 | Cohort 6: Treatment 1 | Cohort 6: Treatment 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time to Response (TTR) Assessed by Blinded Independent Central Review (BICR) | 1.41 (1.4 to 2.8) | 3.15 (2.3 to 4.0) | 1.99 (1.3 to 2.7) | 2.73 (1.3 to 6.8) | 3.63 (2.6 to 5.7) | 2.78 (1.2 to 7.0) | 1.38 (1.2 to 6.8) | 3.50 (1.9 to 5.7) | 2.81 (1.9 to 5.5) | 2.00 (1.1 to 12.8) | 2.58 (1.2 to 5.5) | 2.66 (1.2 to 8.7) | 2.66 (1.4 to 4.2) | 5.13 (1.3 to 5.7) | 4.17 (1.3 to 8.1) |
Time to Progression (TTP) is defined from the date of randomization (Cohort 3, 4, 6) or the date of first dose (Cohort 1, 2, 5) to the date of the first objectively documented disease progression. Participants who have not progressed as assessed by radiography will be censored at the last tumor assessment date prior to subsequent anti-cancer therapy. Participants who have no on-study tumor assessments were censored at the date of randomization. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).
| Months | Cohort 1 Uninfected HCC | Cohort 1 HCV Infected | Cohort 1 HBV Infected | Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1 | Cohort 2 Uninfected Sorafenib Progressors: Treatment 2 | Cohort 2 HCV Infected: Treatment 3 | Cohort 2 HBV Infected: Treatment 4 | Cohort 3: Treatment 1 | Cohort 3: Treatment 2 | Cohort 4: Treatment 1 | Cohort 4: Treatment 2 | Cohort 4: Treatment 3 | Cohort 5: Treatment 1 | Cohort 6: Treatment 1 | Cohort 6: Treatment 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time to Progression (TTP) Assessed by Blinded Independent Central Review (BICR) | 2.66 (1.38 to 4.21) | 8.21 (1.31 to NA) | 2.96 (1.25 to 6.97) | 4.01 (2.76 to 4.63) | 2.79 (1.48 to 5.59) | 3.94 (2.63 to 8.05) | 2.63 (1.38 to 4.04) | 4.83 (1.94 to 5.55) | 4.63 (3.32 to 12.94) | 4.27 (2.63 to 9.69) | 1.68 (1.35 to 13.90) | 2.73 (1.45 to 5.65) | 2.79 (1.41 to 5.36) | 5.42 (2.76 to 11.47) | 11.63 (4.11 to 36.86) |
TTP rate is defined as the percentage of participants without disease progression at select time points (milestones) during the study. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).
| Percent of Participants | Cohort 1 Uninfected HCC | Cohort 1 HCV Infected | Cohort 1 HBV Infected | Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1 | Cohort 2 Uninfected Sorafenib Progressors: Treatment 2 | Cohort 2 HCV Infected: Treatment 3 | Cohort 2 HBV Infected: Treatment 4 | Cohort 3: Treatment 1 | Cohort 3: Treatment 2 | Cohort 4: Treatment 1 | Cohort 4: Treatment 2 | Cohort 4: Treatment 3 | Cohort 5: Treatment 1 | Cohort 6: Treatment 1 | Cohort 6: Treatment 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 Months | 28.6 (11.7 to 48.2) | 60.0 (25.3 to 82.7) | 27.9 (7.1 to 54.1) | 33.9 (21.4 to 46.9) | 32.8 (20.2 to 46.0) | 41.5 (26.9 to 55.5) | 26.0 (14.7 to 38.9) | 30.1 (17.3 to 44.0) | 42.5 (27.2 to 56.9) | 42.5 (28.0 to 56.3) | 43.6 (28.7 to 57.5) | 32.4 (19.3 to 46.2) | 31.6 (16.9 to 47.4) | 42.8 (25.2 to 59.3) | 50.0 (30.3 to 66.9) |
| 12 Months | 17.1 (4.6 to 36.5) | 24.0 (3.8 to 53.7) | 18.6 (3.0 to 44.5) | 21.4 (11.3 to 33.6) | 19.3 (9.0 to 32.4) | 30.9 (17.7 to 45.1) | 13.0 (5.3 to 24.2) | 12.2 (4.1 to 25.0) | 35.4 (20.5 to 50.6) | 33.1 (19.8 to 46.9) | 35.9 (21.9 to 50.1) | 27.6 (15.4 to 41.3) | 14.7 (4.4 to 31.0) | 32.1 (16.5 to 48.9) | 45.0 (25.5 to 62.7) |
PFS is defined as the time from randomization date or first dosing date of study medication to the date of the first objectively documented tumor progression or death due to any cause. Participants who die without a reported prior progression will be considered to have progressed on the date of their death. Participants who did not progress or die will be censored on the date of their last tumor assessment. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression).
| Months | Cohort 1 Uninfected HCC | Cohort 1 HCV Infected | Cohort 1 HBV Infected | Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1 | Cohort 2 Uninfected Sorafenib Progressors: Treatment 2 | Cohort 2 HCV Infected: Treatment 3 | Cohort 2 HBV Infected: Treatment 4 | Cohort 3: Treatment 1 | Cohort 3: Treatment 2 | Cohort 4: Treatment 1 | Cohort 4: Treatment 2 | Cohort 4: Treatment 3 | Cohort 5: Treatment 1 | Cohort 6: Treatment 1 | Cohort 6: Treatment 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) | 2.69 (1.38 to 4.21) | 8.97 (1.31 to 14.06) | 2.96 (1.25 to 4.07) | 4.01 (2.76 to 4.60) | 2.76 (1.48 to 4.40) | 3.94 (2.63 to 7.23) | 2.63 (1.35 to 4.04) | 3.78 (1.84 to 5.45) | 3.91 (3.32 to 5.65) | 3.91 (2.60 to 8.31) | 1.61 (1.35 to 6.93) | 2.63 (1.31 to 4.50) | 2.30 (1.41 to 3.42) | 5.13 (2.76 to 10.91) | 4.27 (3.58 to 11.86) |
OS is defined as the time from randomization date or first dosing date of study medication to the date of death (due to any cause). Participants who were alive were censored at the last known alive dates.
| Months | Cohort 1 Uninfected HCC | Cohort 1 HCV Infected | Cohort 1 HBV Infected | Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1 | Cohort 2 Uninfected Sorafenib Progressors: Treatment 2 | Cohort 2 HCV Infected: Treatment 3 | Cohort 2 HBV Infected: Treatment 4 | Cohort 3: Treatment 1 | Cohort 3: Treatment 2 | Cohort 4: Treatment 1 | Cohort 4: Treatment 2 | Cohort 4: Treatment 3 | Cohort 5: Treatment 1 | Cohort 6: Treatment 1 | Cohort 6: Treatment 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Survival (OS) | 14.32 (5.65 to 18.14) | 36.27 (3.61 to 55.10) | 10.45 (3.68 to 20.21) | 26.68 (17.71 to 34.40) | 13.44 (8.57 to 18.89) | 17.45 (13.04 to 25.66) | 15.64 (9.69 to 20.67) | 15.24 (11.07 to 22.90) | 13.96 (8.71 to 19.25) | 22.24 (9.43 to 54.83) | 12.48 (7.62 to 16.39) | 12.75 (7.43 to 30.52) | 7.85 (4.37 to 10.51) | 20.21 (13.11 to 32.20) | 22.11 (15.15 to 36.50) |
OS rate is defined as the percentage of participants who are still alive at certain time points during the study.
| Percent of Participants | Cohort 1 Uninfected HCC | Cohort 1 HCV Infected | Cohort 1 HBV Infected | Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1 | Cohort 2 Uninfected Sorafenib Progressors: Treatment 2 | Cohort 2 HCV Infected: Treatment 3 | Cohort 2 HBV Infected: Treatment 4 | Cohort 3: Treatment 1 | Cohort 3: Treatment 2 | Cohort 4: Treatment 1 | Cohort 4: Treatment 2 | Cohort 4: Treatment 3 | Cohort 5: Treatment 1 | Cohort 6: Treatment 1 | Cohort 6: Treatment 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 Months | 69.6 (46.6 to 84.2) | 80.0 (40.9 to 94.6) | 53.3 (26.3 to 74.4) | 89.0 (77.0 to 94.9) | 75.4 (62.1 to 84.7) | 83.3 (69.3 to 91.3) | 84.3 (71.1 to 91.8) | 81.3 (68.8 to 89.2) | 76.7 (63.8 to 85.5) | 81.7 (67.7 to 90.0) | 75.0 (60.2 to 85.0) | 73.5 (58.7 to 83.6) | 59.2 (44.2 to 71.4) | 82.4 (64.9 to 91.7) | 82.4 (65.0 to 91.7) |
| 12 Months | 60.9 (38.3 to 77.4) | 80.0 (40.9 to 94.6) | 46.7 (21.2 to 68.7) | 76.0 (62.3 to 85.3) | 54.4 (40.7 to 66.2) | 67.5 (51.9 to 79.0) | 58.8 (44.1 to 70.9) | 57.1 (43.4 to 68.6) | 57.0 (43.2 to 68.6) | 60.7 (45.6 to 72.9) | 56.1 (41.0 to 68.8) | 50.8 (36.1 to 63.7) | 34.7 (21.8 to 47.9) | 70.2 (51.6 to 82.7) | 70.6 (52.3 to 83.0) |
| 24 Months | 26.1 (10.6 to 44.7) | 60.0 (25.3 to 82.7) | 26.7 (8.3 to 49.6) | 57.0 (42.7 to 69.0) | 26.3 (15.7 to 38.1) | 38.9 (24.5 to 53.0) | 36.6 (23.6 to 49.7) | 32.9 (21.3 to 45.0) | 30.4 (18.8 to 42.8) | 46.1 (31.7 to 59.3) | 30.2 (17.9 to 43.5) | 42.3 (28.3 to 55.7) | 10.2 (3.7 to 20.5) | 39.0 (22.6 to 55.2) | 46.1 (28.7 to 61.8) |
| 48 Months | 17.4 (5.4 to 35.0) | 30.0 (7.1 to 57.8) | 6.7 (0.4 to 26.0) | 20.9 (11.2 to 32.7) | 11.7 (4.9 to 21.7) | 14.6 (6.0 to 26.9) | 12.2 (5.0 to 22.9) | 15.6 (7.5 to 26.5) | 8.4 (2.7 to 18.0) | 37.0 (23.5 to 50.6) | 21.6 (11.2 to 34.2) | 25.4 (14.2 to 38.2) | 00 (00 to 00) | 19.0 (7.5 to 34.4) | 30.7 (16.1 to 46.6) |
| 60 Months | 8.7 (1.5 to 24.2) | 15.0 (1.0 to 45.7) | 6.7 (0.4 to 26.0) | 15.2 (7.1 to 26.1) | 9.7 (3.7 to 19.3) | 14.6 (6.0 to 26.9) | 12.2 (5.0 to 22.9) | 8.9 (3.0 to 18.8) | 5.6 (1.2 to 15.1) | 29.6 (17.1 to 43.2) | 19.2 (9.4 to 31.6) | 21.2 (11.0 to 33.6) | 00 (00 to 00) | 15.2 (5.1 to 30.2) | 24.6 (11.6 to 40.0) |
Cmax is the maximum observed serum concentration.
| ug/mL | Cohort 1 Uninfected HCC | Cohort 1 HCV Infected | Cohort 1 HBV Infected |
|---|---|---|---|
| Cycle 1 Day 1 | 60.06 ± 335.87 | 19.81 ± 109.88 | 9.82 ± 244.81 |
| Cycle 3 Day 1 | 100.74 ± 339.27 | 23.09 ± 130.66 | 15.54 ± 379.81 |
Tmax is the time taken to reach the maximum observed serum concentration (Cmax).
| Hour | Cohort 1 Uninfected HCC | Cohort 1 HCV Infected | Cohort 1 HBV Infected |
|---|---|---|---|
| Cycle 1 Day 1 | 3.00 (1.0 to 25.2) | 2.98 (0.9 to 25.2) | 3.00 (0.9 to 23.9) |
| Cycle 3 Day 1 | 12.75 (0.9 to 24.3) | 12.28 (1.0 to 24.5) | 24.13 (0.8 to 25.7) |
AUC (TAU) is the area measured under the concentration-time curve taken over the dosing interval.
| ug.h/mL | Cohort 1 Uninfected HCC | Cohort 1 HCV Infected | Cohort 1 HBV Infected |
|---|---|---|---|
| Cycle 1 Day 1 | 9114.43 ± 366.71 | 2825.09 ± 159.47 | 1313.76 ± 287.76 |
| Cycle 3 Day 1 | 15229.27 ± 383.94 | 3358.78 ± 79.68 | 3731.16 ± 505.00 |
Ctrough is the lowest observed serum concentration.
| ug/mL | Cohort 1 Uninfected HCC | Cohort 1 HCV Infected | Cohort 1 HBV Infected |
|---|---|---|---|
| Cycle 1 Day 1 | 16.52 ± 383.95 | 4.40 ± 194.65 | 2.26 ± 412.75 |
| Cycle 3 Day 1 | 32.48 ± 430.86 | 6.76 ± 97.21 | 8.51 ± 473.58 |
Serum Concentration Achieved at the End of the Infusion (Ceoinf) refers to the amount of drug present in the blood (serum) immediately after the completion of an infusion. It represents the concentration measured at the exact time the infusion ends, before any significant elimination or distribution occurs.
| ug/mL | Cohort 1 Uninfected HCC | Cohort 1 HCV Infected | Cohort 1 HBV Infected |
|---|---|---|---|
| Cycle 1 Day 1 | 49.88 ± 315.39 | 17.07 ± 123.95 | 6.99 ± 254.53 |
| Cycle 3 Day 1 | 84.36 ± 371.92 | 25.53 ± 147.16 | 11.80 ± 353.06 |
AI\_Cmax is ratio of an exposure measure at steady state to that after the first dose (exposure measure includes Cmax)
| Ratio | Cohort 1 Uninfected HCC | Cohort 1 HCV Infected | Cohort 1 HBV Infected |
|---|---|---|---|
| Ratio of an Exposure Measure at Steady State to That After the First Dose (Exposure Measure Includes Cmax) (AI_Cmax) | 2.26 ± 69.85 | 1.53 ± 23.34 | 1.45 ± 23.94 |
AI\_AUC is accumulation index ratio of AUC at steady state to that after the first dose
| Ratio | Cohort 1 Uninfected HCC | Cohort 1 HCV Infected | Cohort 1 HBV Infected |
|---|---|---|---|
| Accumulation Index Ratio of AUC at Steady State to That After the First Dose (AI_AUC) | 2.60 ± 24.54 | 2.23 ± 9.80 | 2.28 ± 8.90 |
Effective half-life is defined as the time it takes for the amount of a drug in the body to decrease by half.
| Hour | Cohort 1 Uninfected HCC | Cohort 1 HCV Infected | Cohort 1 HBV Infected |
|---|---|---|---|
| Effective T-Half (T-HALF) | 468.07 ± 27.65 | 382.36 ± 15.52 | 406.60 ± 15.65 |
Baseline ADA Positive: Participant with baseline ADA-positive sample ADA Positive: Participant with at least one ADA-positive sample relative to baseline Persistent Positive (PP): ADA-positive sample at 2 or more consecutive timepoints Not PP-Last Sample Positive: Not persistent but with ADA-positive sample at the last sampling timepoint Other Positive: Not persistent but some ADA-positive samples with the last sample being negative ADA Negative: Participant with no ADA-positive sample after initiation of treatment
| Participants | Cohort 1 Uninfected HCC: Treatment 1 | Cohort 1 Uninfected HCC: Treatment 2 | Cohort 1 Uninfected HCC: Treatment 3 | Cohort 1 Uninfected HCC: Treatment 4 | Cohort 1 Uninfected HCC: Treatment 5 | Cohort 1 HCV Infected: Treatment 6 | Cohort 1 HCV Infected: Treatment 7 | Cohort 1 HCV Infected: Treatment 8 | Cohort 1 HBV Infected: Treatment 9 | Cohort 1 HBV Infected: Treatment 10 | Cohort 1 HBV Infected: Treatment 11 | Cohort 1 HBV Infected: Treatment 12 | Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1 | Cohort 2 Uninfected Sorafenib Progressors: Treatment 2 | Cohort 2 HCV Infected: Treatment 3 | Cohort 2 HBV Infected: Treatment 4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline ADA Positive | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 3 | 5 | 1 |
| ADA Positive | 0 | 2 | 2 | 0 | 1 | 2 | 1 | 0 | 1 | 1 | 1 | 1 | 18 | 19 | 16 | 7 |
| ADA Positive [Persistent Positive (PP)] | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 1 | 3 | 0 |
| ADA Positive [Not PP-Last Sample Positive] | 0 | 2 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 4 | 3 | 9 | 1 |
| ADA Positive [Other Positive] | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 1 | 12 | 15 | 4 | 6 |
| Neutralizing Positive | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| ADA Negative | 1 | 1 | 1 | 3 | 11 | 1 | 3 | 3 | 4 | 2 | 2 | 3 | 35 | 35 | 28 | 43 |
Collected over Participants were assessed for All-Cause Mortality from the date of their randomization (Cohorts 3, 4, and 6) or first dose (Cohorts 1, 2, and 5) until study completion (assessed up to approximately 144 months). SAEs and Other AEs were assessed from first dose of study medication through 100 days following last dose of study treatment (Assessed for approximately 04 months up to a max of approximately 106 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 Uninfected HCC: Treatment 1 | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) |
| Cohort 1 Uninfected HCC: Treatment 2 | 3/3 (100%) | 1/3 (33.3%) | 3/3 (100%) |
| Cohort 1 Uninfected HCC: Treatment 3 | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| Cohort 1 Uninfected HCC: Treatment 4 | 2/3 (66.7%) | 0/3 (0%) | 3/3 (100%) |
| Cohort 1 Uninfected HCC: Treatment 5 | 13/13 (100%) | 8/13 (61.5%) | 13/13 (100%) |
| Cohort 1 HCV Infected: Treatment 6 | 1/3 (33.3%) | 0/3 (0%) | 3/3 (100%) |
| Cohort 1 HCV Infected: Treatment 7 | 4/4 (100%) | 3/4 (75%) | 4/4 (100%) |
| Cohort 1 HCV Infected: Treatment 8 | 3/3 (100%) | 1/3 (33.3%) | 3/3 (100%) |
| Cohort 1 HBV Infected: Treatment 9 | 5/5 (100%) | 5/5 (100%) | 5/5 (100%) |
| Cohort 1 HBV Infected: Treatment 10 | 3/3 (100%) | 3/3 (100%) | 3/3 (100%) |
| Cohort 1 HBV Infected: Treatment 11 | 3/3 (100%) | 1/3 (33.3%) | 3/3 (100%) |
| Cohort 1 HBV Infected: Treatment 12 | 4/4 (100%) | 3/4 (75%) | 4/4 (100%) |
| Cohort 2: Nivolumab 3 mg/kg | 186/214 (86.9%) | 137/214 (64%) | 210/214 (98.1%) |
| Cohort 3: Treatment 1 | 52/61 (85.2%) | 35/60 (58.3%) | 55/60 (91.7%) |
| Cohort 3: Treatment 2 | 53/66 (80.3%) | 33/62 (53.2%) | 57/62 (91.9%) |
| Cohort 4: Treatment 1 | 36/50 (72%) | 35/49 (71.4%) | 47/49 (95.9%) |
| Cohort 4: Treatment 2 | 41/49 (83.7%) | 36/49 (73.5%) | 47/49 (95.9%) |
| Cohort 4: Treatment 3 | 41/49 (83.7%) | 36/48 (75%) | 45/48 (93.8%) |
| Cohort 5: Treatment 1 | 48/49 (98%) | 37/49 (75.5%) | 42/49 (85.7%) |
| Cohort 6: Treatment 1 | 29/36 (80.6%) | 22/36 (61.1%) | 36/36 (100%) |
| Cohort 6: Treatment 2 | 26/35 (74.3%) | 25/35 (71.4%) | 35/35 (100%) |
| Event | Cohort 1 Uninfected HCC: Treatment 1 | Cohort 1 Uninfected HCC: Treatment 2 | Cohort 1 Uninfected HCC: Treatment 3 | Cohort 1 Uninfected HCC: Treatment 4 | Cohort 1 Uninfected HCC: Treatment 5 | Cohort 1 HCV Infected: Treatment 6 | Cohort 1 HCV Infected: Treatment 7 | Cohort 1 HCV Infected: Treatment 8 | Cohort 1 HBV Infected: Treatment 9 | Cohort 1 HBV Infected: Treatment 10 | Cohort 1 HBV Infected: Treatment 11 | Cohort 1 HBV Infected: Treatment 12 | Cohort 2: Nivolumab 3 mg/kg | Cohort 3: Treatment 1 | Cohort 3: Treatment 2 | Cohort 4: Treatment 1 | Cohort 4: Treatment 2 | Cohort 4: Treatment 3 | Cohort 5: Treatment 1 | Cohort 6: Treatment 1 | Cohort 6: Treatment 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/1 | 0/3 | 1/3 | 0/3 | 4/13 | 0/3 | 2/4 | 0/3 | 1/5 | 2/3 | 0/3 | 3/4 | 52/214 | 10/60 | 10/62 | 12/49 | 15/49 | 18/48 | 18/49 | 6/36 | 5/35 |
| AscitesGastrointestinal disorders | 0/1 | 0/3 | 0/3 | 0/3 | 0/13 | 0/3 | 0/4 | 0/3 | 0/5 | 1/3 | 1/3 | 2/4 | 4/214 | 1/60 | 6/62 | 2/49 | 1/49 | 3/48 | 3/49 | 0/36 | 0/35 |
| AnaemiaBlood and lymphatic system disorders | 0/1 | 0/3 | 0/3 | 0/3 | 0/13 | 0/3 | 0/4 | 0/3 | 0/5 | 1/3 | 0/3 | 1/4 | 3/214 | 0/60 | 0/62 | 3/49 | 3/49 | 2/48 | 1/49 | 1/36 | 0/35 |
| Adrenal insufficiencyEndocrine disorders | 0/1 | 0/3 | 0/3 | 0/3 | 0/13 | 0/3 | 0/4 | 0/3 | 0/5 | 1/3 | 0/3 | 0/4 | 0/214 | 2/60 | 1/62 | 2/49 | 0/49 | 0/48 | 0/49 | 0/36 | 1/35 |
| Non-cardiac chest painGeneral disorders | 0/1 | 1/3 | 0/3 | 0/3 | 0/13 | 0/3 | 0/4 | 0/3 | 0/5 | 0/3 | 0/3 | 0/4 | 1/214 | 0/60 | 0/62 | 0/49 | 0/49 | 0/48 | 0/49 | 0/36 | 0/35 |
| PyrexiaGeneral disorders | 0/1 | 0/3 | 0/3 | 0/3 | 0/13 | 0/3 | 0/4 | 0/3 | 0/5 | 1/3 | 0/3 | 0/4 | 7/214 | 2/60 | 0/62 | 4/49 | 3/49 | 4/48 | 0/49 | 3/36 | 0/35 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/1 | 0/3 | 1/3 | 0/3 | 0/13 | 0/3 | 0/4 | 0/3 | 1/5 | 0/3 | 0/3 | 1/4 | 1/214 | 0/60 | 0/62 | 1/49 | 1/49 | 1/48 | 0/49 | 0/36 | 0/35 |
| Neck painMusculoskeletal and connective tissue disorders | 0/1 | 0/3 | 1/3 | 0/3 | 0/13 | 0/3 | 0/4 | 0/3 | 0/5 | 0/3 | 0/3 | 0/4 | 0/214 | 0/60 | 0/62 | 0/49 | 0/49 | 0/48 | 0/49 | 0/36 | 0/35 |
| CholangiocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/1 | 0/3 | 1/3 | 0/3 | 0/13 | 0/3 | 0/4 | 0/3 | 0/5 | 0/3 | 0/3 | 0/4 | 0/214 | 0/60 | 0/62 | 0/49 | 0/49 | 0/48 | 0/49 | 0/36 | 0/35 |
| Neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/1 | 0/3 | 0/3 | 0/3 | 0/13 | 0/3 | 0/4 | 0/3 | 0/5 | 0/3 | 1/3 | 0/4 | 0/214 | 0/60 | 0/62 | 0/49 | 0/49 | 0/48 | 0/49 | 0/36 | 0/35 |
| Event | Cohort 1 Uninfected HCC: Treatment 1 | Cohort 1 Uninfected HCC: Treatment 2 | Cohort 1 Uninfected HCC: Treatment 3 | Cohort 1 Uninfected HCC: Treatment 4 | Cohort 1 Uninfected HCC: Treatment 5 | Cohort 1 HCV Infected: Treatment 6 | Cohort 1 HCV Infected: Treatment 7 | Cohort 1 HCV Infected: Treatment 8 | Cohort 1 HBV Infected: Treatment 9 | Cohort 1 HBV Infected: Treatment 10 | Cohort 1 HBV Infected: Treatment 11 | Cohort 1 HBV Infected: Treatment 12 | Cohort 2: Nivolumab 3 mg/kg | Cohort 3: Treatment 1 | Cohort 3: Treatment 2 | Cohort 4: Treatment 1 | Cohort 4: Treatment 2 | Cohort 4: Treatment 3 | Cohort 5: Treatment 1 | Cohort 6: Treatment 1 | Cohort 6: Treatment 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AscitesGastrointestinal disorders | 1/1 | 0/3 | 0/3 | 0/3 | 1/13 | 0/3 | 1/4 | 0/3 | 0/5 | 1/3 | 0/3 | 3/4 | 22/214 | 6/60 | 10/62 | 8/49 | 6/49 | 8/48 | 18/49 | 6/36 | 3/35 |
| DiarrhoeaGastrointestinal disorders | 1/1 | 1/3 | 0/3 | 0/3 | 4/13 | 3/3 | 1/4 | 0/3 | 1/5 | 1/3 | 2/3 | 2/4 | 61/214 | 11/60 | 32/62 | 19/49 | 11/49 | 19/48 | 9/49 | 21/36 | 15/35 |
| VomitingGastrointestinal disorders | 1/1 | 0/3 | 0/3 | 0/3 | 3/13 | 0/3 | 0/4 | 0/3 | 1/5 | 0/3 | 0/3 | 1/4 | 37/214 | 8/60 | 6/62 | 6/49 | 10/49 | 7/48 | 0/49 | 5/36 | 7/35 |
| Oedema peripheralGeneral disorders | 1/1 | 0/3 | 0/3 | 0/3 | 1/13 | 0/3 | 0/4 | 1/3 | 0/5 | 1/3 | 0/3 | 2/4 | 35/214 | 8/60 | 7/62 | 10/49 | 11/49 | 14/48 | 13/49 | 4/36 | 7/35 |
| Upper respiratory tract infectionInfections and infestations | 0/1 | 0/3 | 0/3 | 0/3 | 1/13 | 3/3 | 0/4 | 0/3 | 3/5 | 1/3 | 0/3 | 0/4 | 13/214 | 2/60 | 1/62 | 1/49 | 6/49 | 2/48 | 2/49 | 2/36 | 2/35 |
| Aspartate aminotransferase increasedInvestigations | 1/1 | 0/3 | 1/3 | 1/3 | 4/13 | 2/3 | 2/4 | 0/3 | 2/5 | 0/3 | 1/3 | 1/4 | 38/214 | 10/60 | 10/62 | 17/49 | 16/49 | 11/48 | 6/49 | 10/36 | 15/35 |
| Blood alkaline phosphatase increasedInvestigations | 1/1 | 0/3 | 1/3 | 0/3 | 1/13 | 0/3 | 0/4 | 0/3 | 2/5 | 0/3 | 0/3 | 1/4 | 12/214 | 3/60 | 5/62 | 6/49 | 3/49 | 5/48 | 0/49 | 3/36 | 6/35 |
| Decreased appetiteMetabolism and nutrition disorders | 1/1 | 0/3 | 0/3 | 0/3 | 4/13 | 0/3 | 3/4 | 0/3 | 2/5 | 2/3 | 2/3 | 3/4 | 57/214 | 12/60 | 22/62 | 20/49 | 13/49 | 15/48 | 2/49 | 8/36 | 8/35 |
| HyponatraemiaMetabolism and nutrition disorders | 1/1 | 0/3 | 2/3 | 1/3 | 2/13 | 1/3 | 3/4 | 1/3 | 0/5 | 0/3 | 0/3 | 1/4 | 7/214 | 8/60 | 3/62 | 9/49 | 4/49 | 6/48 | 2/49 | 1/36 | 3/35 |
| FatigueGeneral disorders | 0/1 | 1/3 | 0/3 | 1/3 | 5/13 | 1/3 | 3/4 | 0/3 | 2/5 | 1/3 | 0/3 | 1/4 | 86/214 | 23/60 | 21/62 | 11/49 | 11/49 | 13/48 | 5/49 | 10/36 | 11/35 |
| Age, Categorical(Participants) | Cohort 1 Uninfected HCC: Treatment 1 | Cohort 1 Uninfected HCC: Treatment 2 | Cohort 1 Uninfected HCC: Treatment 3 | Cohort 1 Uninfected HCC: Treatment 4 | Cohort 1 Uninfected HCC: Treatment 5 | Cohort 1 HCV Infected: Treatment 6 | Cohort 1 HCV Infected: Treatment 7 | Cohort 1 HCV Infected: Treatment 8 | Cohort 1 HBV Infected: Treatment 9 | Cohort 1 HBV Infected: Treatment 10 | Cohort 1 HBV Infected: Treatment 11 | Cohort 1 HBV Infected: Treatment 12 | Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1 | Cohort 2 Uninfected Sorafenib Progressors: Treatment 2 | Cohort 2 HCV Infected: Treatment 3 | Cohort 2 HBV Infected: Treatment 4 | Cohort 3: Treatment 1 | Cohort 3: Treatment 2 | Cohort 4: Treatment 1 | Cohort 4: Treatment 2 | Cohort 4: Treatment 3 | Cohort 5: Treatment 1 | Cohort 6: Treatment 1 | Cohort 6: Treatment 2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 2 | 1 | 2 | 9 | 2 | 2 | 0 | 1 | 2 | 3 | 3 | 23 | 28 | 25 | 38 | 24 | 33 | 31 | 24 | 36 | 16 | 18 | 16 | 340 |
| >=65 years | 0 | 1 | 2 | 1 | 4 | 1 | 2 | 3 | 4 | 1 | 0 | 1 | 33 | 29 | 25 | 13 | 37 | 33 | 19 | 25 | 13 | 33 | 18 | 19 | 317 |
| Sex: Female, Male(Participants) | Cohort 1 Uninfected HCC: Treatment 1 | Cohort 1 Uninfected HCC: Treatment 2 | Cohort 1 Uninfected HCC: Treatment 3 | Cohort 1 Uninfected HCC: Treatment 4 | Cohort 1 Uninfected HCC: Treatment 5 | Cohort 1 HCV Infected: Treatment 6 | Cohort 1 HCV Infected: Treatment 7 | Cohort 1 HCV Infected: Treatment 8 | Cohort 1 HBV Infected: Treatment 9 | Cohort 1 HBV Infected: Treatment 10 | Cohort 1 HBV Infected: Treatment 11 | Cohort 1 HBV Infected: Treatment 12 | Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1 | Cohort 2 Uninfected Sorafenib Progressors: Treatment 2 | Cohort 2 HCV Infected: Treatment 3 | Cohort 2 HBV Infected: Treatment 4 | Cohort 3: Treatment 1 | Cohort 3: Treatment 2 | Cohort 4: Treatment 1 | Cohort 4: Treatment 2 | Cohort 4: Treatment 3 | Cohort 5: Treatment 1 | Cohort 6: Treatment 1 | Cohort 6: Treatment 2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 2 | 0 | 1 | 3 | 1 | 1 | 2 | 1 | 0 | 1 | 0 | 8 | 15 | 8 | 12 | 10 | 10 | 7 | 12 | 9 | 10 | 4 | 5 | 122 |
| Male | 1 | 1 | 3 | 2 | 10 | 2 | 3 | 1 | 4 | 3 | 2 | 4 | 48 | 42 | 42 | 39 | 51 | 56 | 43 | 37 | 40 | 39 | 32 | 30 | 535 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 Uninfected HCC: Treatment 1 | Cohort 1 Uninfected HCC: Treatment 2 | Cohort 1 Uninfected HCC: Treatment 3 | Cohort 1 Uninfected HCC: Treatment 4 | Cohort 1 Uninfected HCC: Treatment 5 | Cohort 1 HCV Infected: Treatment 6 | Cohort 1 HCV Infected: Treatment 7 | Cohort 1 HCV Infected: Treatment 8 | Cohort 1 HBV Infected: Treatment 9 | Cohort 1 HBV Infected: Treatment 10 | Cohort 1 HBV Infected: Treatment 11 | Cohort 1 HBV Infected: Treatment 12 | Cohort 2 Uninfected Sorafenib Naive/Intolerant: Treatment 1 | Cohort 2 Uninfected Sorafenib Progressors: Treatment 2 | Cohort 2 HCV Infected: Treatment 3 | Cohort 2 HBV Infected: Treatment 4 | Cohort 3: Treatment 1 | Cohort 3: Treatment 2 | Cohort 4: Treatment 1 | Cohort 4: Treatment 2 | Cohort 4: Treatment 3 | Cohort 5: Treatment 1 | Cohort 6: Treatment 1 | Cohort 6: Treatment 2 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 0 | 2 | 3 | 3 | 11 | 3 | 3 | 2 | 1 | 0 | 0 | 0 | 38 | 34 | 29 | 4 | 39 | 42 | 12 | 20 | 15 | 27 | 26 | 23 | 337 |
| Black or African American | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 1 | 2 | 1 | 1 | 3 | 2 | 2 | 1 | 21 |
| Asian | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 4 | 3 | 3 | 4 | 16 | 22 | 18 | 45 | 19 | 21 | 37 | 27 | 30 | 20 | 8 | 10 | 291 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 6 |
| Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2012 to primary completion in Nov 2024, 144 months.
Results were first posted in Dec 2025, 1 year 1 month after primary completion.
Of 72 industry-sponsored phase 1/2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 74. This study's 144 months is above that.
Counting every sponsor, half of 136 studies reached it within 53 months; a quarter within 38 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Cabozantinib